Female dystrophin mutation carriers present with dilated cardiomyopathy in approximately 8% of cases, with prevalence ranging from 0% to 16.7% depending on DMD or BMD classification.
This review highlights the significant risk of dilated cardiomyopathy in female dystrophin mutation carriers, emphasizing the need for cardiac monitoring and potential therapies.
Duchenne muscular dystrophy (DMD) is a fatal X-linked recessive condition caused primarily by out-of-frame mutations in the dystrophin gene. In males, DMD presents with progressive body-wide muscle deterioration, culminating in death as a result of cardiac or respiratory failure. A milder form of DMD exists, called Becker muscular dystrophy (BMD), which is typically caused by in-frame dystrophin gene mutations. It should be emphasized that DMD and BMD are not exclusive to males, as some female dystrophin mutation carriers do present with similar symptoms, generally at reduced levels of severity. Cardiac involvement in particular is a pressing concern among manifesting females, as it may develop into serious heart failure or could predispose them to certain risks during pregnancy or daily life activities. It is known that about 8% of carriers present with dilated cardiomyopathy, though it may vary from 0% to 16.7%, depending on if the carrier is classified as having DMD or BMD. Understanding the genetic and molecular mechanisms underlying cardiac manifestations in dystrophin-deficient females is therefore of critical importance. In this article, we review available information from the literature on this subject, as well as discuss the implications of female carrier studies on the development of therapies aiming to increase dystrophin levels in the heart.
Lim et al. (Wed,) conducted a review in Dystrophinopathies (DMD/BMD) in female carriers. Female dystrophin mutation carriers present with dilated cardiomyopathy in approximately 8% of cases, with prevalence ranging from 0% to 16.7% depending on DMD or BMD classification.